CMAUP Plant Collective Molecular Activities

Plant Name: Aconitum carmichaeli

Collective Molecular Activities at 10μM Activity Cutoff

List of Human Proteins Collectively Targeted by the Plant

Target Activity Range: ≤ 10μM
Click Gene ID to Access Activity Profile of Individual Target

Target Class	Target Proteins

List of Human Cytochrome P450 Enzymes Affected by the Plant

Activity Range: ≤ 10μM
Click Gene ID to Access Activity Profile of Individual Enzyme

Cytochrome P450 Enzymes:

Detailed Information of Human Protein Targets

Protein Class	Gene ID	Protein Name	Uniprot ID	Target ChEMBL ID

Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)

Detailed Information of Enriched Gene Ontolgy

GO Type	GO Category	Enriched GO Terms	p-Value	Adjusted p-Value	Enriched Genes
BP	GO:0008152; metabolic process	GO:0006730; one-carbon metabolic process	3.296E-13	1.248E-09	CA1, CA12, CA2, CA3, CA7, CA9
BP	Unclassified;	GO:2000021; regulation of ion homeostasis	2.694E-10	4.512E-07	CA2, CA7, DRD2, DRD3, HTR2A, HTR2B, HTR2C
BP	GO:0007610; behavior	GO:0048148; behavioral response to cocaine	1.972E-09	2.147E-06	DRD2, DRD3, DRD4, HTR2A
BP	Unclassified;	GO:0032844; regulation of homeostatic process	2.524E-09	2.617E-06	CA2, CA7, DRD2, DRD3, HIF1A, HTR2A, HTR2B, HTR2C
BP	GO:0008152; metabolic process	GO:0010513; positive regulation of phosphatidylinositol biosynthetic process	5.656E-09	5.355E-06	HTR2A, HTR2B, HTR2C
MF	GO:0060089; molecular transducer activity	GO:0001591; dopamine neurotransmitter receptor activity, coupled via Gi/Go	3.162E-08	2.374E-05	DRD2, DRD3, DRD4
BP	GO:0051179; localization	GO:0051209; release of sequestered calcium ion into cytosol	5.982E-08	3.520E-05	DRD2, HTR2A, HTR2B, HTR2C
BP	GO:0009987; cellular process	GO:0007195; adenylate cyclase-inhibiting dopamine receptor signaling pathway	6.769E-08	3.779E-05	DRD2, DRD3, DRD4
BP	GO:0050896; response to stimulus	GO:0034776; response to histamine	9.302E-08	4.560E-05	DRD2, DRD3, DRD4
BP	GO:0009987; cellular process	GO:0002031; G-protein coupled receptor internalization	9.302E-08	4.560E-05	DRD2, DRD3, HTR2B
MF	GO:0005488; binding	GO:0051378; serotonin binding	9.302E-08	4.560E-05	HTR2A, HTR2B, HTR2C
MF	GO:0005488; binding	GO:0035240; dopamine binding	1.611E-07	6.744E-05	DRD2, DRD3, DRD4
BP	GO:0009987; cellular process	GO:0007208; phospholipase C-activating serotonin receptor signaling pathway	7.290E-07	2.301E-04	HTR2A, HTR2C
MF	GO:0005488; binding	GO:0071886; 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding	7.290E-07	2.301E-04	HTR2A, HTR2C
BP	GO:0051179; localization	GO:0050482; arachidonic acid secretion	9.919E-07	2.833E-04	DRD2, DRD3, DRD4
BP	GO:0009987; cellular process	GO:0007210; serotonin receptor signaling pathway	1.133E-06	3.046E-04	HTR2A, HTR2B, HTR2C
MF	GO:0060089; molecular transducer activity	GO:0004993; G-protein coupled serotonin receptor activity	1.133E-06	3.046E-04	HTR2A, HTR2B, HTR2C
BP	Unclassified;	GO:0032846; positive regulation of homeostatic process	1.157E-06	3.074E-04	CA2, CA7, DRD2, DRD3, HIF1A
BP	GO:0050896; response to stimulus	GO:0001975; response to amphetamine	1.454E-06	3.724E-04	DRD2, DRD3, DRD4
BP	GO:0008152; metabolic process	GO:0042417; dopamine metabolic process	1.830E-06	4.477E-04	DRD2, DRD3, DRD4
BP	GO:0009987; cellular process	GO:0014059; regulation of dopamine secretion	1.830E-06	4.477E-04	DRD2, DRD3, HTR2A
BP	GO:0009987; cellular process	GO:0060160; negative regulation of dopamine receptor signaling pathway	2.186E-06	5.011E-04	DRD2, DRD3
BP	GO:0009987; cellular process	GO:0032849; positive regulation of cellular pH reduction	2.186E-06	5.011E-04	CA2, CA7
BP	GO:0023052; signaling	GO:0051586; positive regulation of dopamine uptake involved in synaptic transmission	2.186E-06	5.011E-04	DRD2, DRD4
BP	GO:0065007; biological regulation	GO:0007194; negative regulation of adenylate cyclase activity	2.764E-06	6.024E-04	DRD2, DRD3, DRD4
BP	Unclassified;	GO:0032845; negative regulation of homeostatic process	6.538E-06	1.186E-03	DRD2, HTR2A, HTR2B, HTR2C
BP	GO:0040011; locomotion	GO:0090325; regulation of locomotion involved in locomotory behavior	7.279E-06	1.277E-03	DRD2, DRD3
BP	GO:0007610; behavior	GO:0008542; visual learning	9.556E-06	1.553E-03	DRD2, DRD3, HIF1A
BP	Unclassified;	GO:0032415; regulation of sodium:proton antiporter activity	1.091E-05	1.710E-03	DRD3, DRD4
MF	GO:0003824; catalytic activity	GO:0004064; arylesterase activity	1.091E-05	1.710E-03	CA1, CA2
BP	GO:0050896; response to stimulus	GO:0009628; response to abiotic stimulus	1.249E-05	1.929E-03	CA2, DRD2, DRD3, HIF1A, HTR2A, HTR2B, LMNA
BP	GO:0007610; behavior	GO:0007626; locomotory behavior	1.545E-05	2.304E-03	DRD2, DRD3, DRD4, HTR2C
BP	GO:0009987; cellular process	GO:0070374; positive regulation of ERK1 and ERK2 cascade	2.251E-05	3.268E-03	DRD2, HTR2A, HTR2B, HTR2C
BP	GO:0009987; cellular process	GO:0007189; adenylate cyclase-activating G-protein coupled receptor signaling pathway	3.252E-05	4.392E-03	DRD2, DRD3, TSHR
BP	GO:0051179; localization	GO:2001225; regulation of chloride transport	3.267E-05	4.392E-03	CA2, CA7
MF	GO:0005488; binding	GO:0008270; zinc ion binding	4.532E-05	5.805E-03	CA1, CA12, CA2, CA3, CA7, CA9
BP	GO:0051179; localization	GO:0002028; regulation of sodium ion transport	4.981E-05	6.198E-03	DRD2, DRD3, DRD4
MF	Unclassified;	GO:0099600; transmembrane receptor activity	5.241E-05	6.386E-03	DRD2, DRD3, DRD4, HTR2A, HTR2B, HTR2C, TSHR
BP	GO:0050896; response to stimulus	GO:0060134; prepulse inhibition	5.654E-05	6.728E-03	DRD2, DRD3
BP	GO:0023052; signaling	GO:0032230; positive regulation of synaptic transmission, GABAergic	5.654E-05	6.728E-03	CA2, CA7
BP	GO:0032501; multicellular organismal process	GO:0035815; positive regulation of renal sodium excretion	5.654E-05	6.728E-03	DRD2, DRD3
BP	GO:0007610; behavior	GO:0048149; behavioral response to ethanol	6.593E-05	7.596E-03	DRD2, DRD4
BP	GO:0023052; signaling	GO:0051967; negative regulation of synaptic transmission, glutamatergic	6.593E-05	7.596E-03	DRD2, HTR2A
MF	GO:0003824; catalytic activity	GO:0004089; carbonate dehydratase activity	6.271E-19	1.365E-14	CA1, CA12, CA14, CA2, CA3, CA7, CA9
BP	GO:0051179; localization	GO:0015701; bicarbonate transport	3.686E-15	4.013E-11	CA1, CA12, CA14, CA2, CA3, CA7, CA9

Enriched KEGG Pathways of Target Proteins (Activity≤10μM)

Top 10, ordered by adjusted p-value

Detailed Information of Enriched KEGG Pathways

Pathway ID	Pathway Name	p-Value	Adjusted p-Value	Enriched Genes
hsa00910	Nitrogen metabolism_Homo sapiens_hsa00910	1.484E-18	5.195E-17	CA12; CA1; CA3; CA2; CA7; CA9; CA14
hsa04080	Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080	1.566E-09	2.740E-08	HTR2B; HTR2C; HTR2A; DRD2; DRD3; DRD4; TSHR
hsa04540	Gap junction_Homo sapiens_hsa04540	7.971E-07	9.299E-06	HTR2B; HTR2C; HTR2A; DRD2
hsa04750	Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750	7.380E-05	6.458E-04	HTR2B; HTR2C; HTR2A
hsa04726	Serotonergic synapse_Homo sapiens_hsa04726	1.098E-04	7.685E-04	HTR2B; HTR2C; HTR2A
hsa04728	Dopaminergic synapse_Homo sapiens_hsa04728	1.669E-04	9.733E-04	DRD2; DRD3; DRD4
hsa04020	Calcium signaling pathway_Homo sapiens_hsa04020	4.443E-04	2.221E-03	HTR2B; HTR2C; HTR2A

Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)

Detailed Information of Human Diseases

ICD10 Disease Category	Disease Name	ICD10 Code	Linked Targets
I00-I99: Diseases of the circulatory system	Cardiotonic	I50	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Mood disorder	F30-F39	HTR2A; HTR2C
NA: NA	Sleep initiation and maintenance disorders	NA	HTR2C
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Sleep disorders	F51, G47	HTR2A
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Sleep maintenance insomnia	F51.0, G47.0	HTR2A
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Bipolar disorder	F31, F40-F42	DRD2; DRD2; DRD2; DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Schizophrenia	F20	HTR2A; HTR2A; DRD3; HTR2C; DRD2; DRD2; DRD2; DRD2; DRD4
E00-E89: Endocrine, nutritional and metabolic diseases	Acromegaly	E22.0	DRD2
I00-I99: Diseases of the circulatory system	Cardiac failure	I50	DRD2
I00-I99: Diseases of the circulatory system	Cardiovascular disorder	I00-I99	HTR2A
J00-J99: Diseases of the respiratory system	Chronic obstructive pulmonary disease	J40-J44, J47	DRD2
C00-D49: Neoplasms	Renal cancer	C64	CA9
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Sexual dysfunction	F52	DRD2
NA: NA	Peripheral vasoconstriction	NA	DRD2
G00-G99: Diseases of the nervous system G00-G99	Pain	G64, G90.0, R52, G89	HTR2C; DRD2
G00-G99: Diseases of the nervous system G00-G99	Parkinson's disease	G20	DRD2
K00-K95: Diseases of the digestive system	Pancreatitis	K85, K86.0K86.1	HTR2A
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Cocaine addiction	F14.2	DRD3
I00-I99: Diseases of the circulatory system	Pulmonary hypertension	I27.0, I27.2	DRD2
G00-G99: Diseases of the nervous system G00-G99	Central nervous system disease	G00-G99	HTR2A
I00-I99: Diseases of the circulatory system	Cerebral infarction	I63	HTR2B
I00-I99: Diseases of the circulatory system	Cerebrovascular ischaemia	I61-I63	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychoses	F20-F29	HTR2B
I00-I99: Diseases of the circulatory system	Pulmonary arterial hypertension	I27.0, I27.2	HTR2B; HIF1A
I00-I99: Diseases of the circulatory system	Hypotension	I95	DRD2
G00-G99: Diseases of the nervous system G00-G99	Alzheimer disease	G30	DRD2
H00-H59: Diseases of the eye and adnexa	Chronic glaucoma	H40-H42	CA1
C00-D49: Neoplasms	Aggressive non-hodgkin's lymphoma	C81, C81-C86, C82-C85, C91-C95	HTR2C
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Advanced stage Parkinson's disease	F02.3, G20	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Alcohol use disorders	F10.2	HTR2A; HTR2C; DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Drug abuse	F10-F19	DRD3; HTR2C
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure	Diagnostic test to differentiate primary and secondary hypothyroidism	W88	TSHR
NA: NA	Addiction	NA	HTR2A
A00-B99: Certain infectious and parasitic diseases	Irritable bowel syndrome	A09, K58, K59.1	HTR2B
NA: NA	Itching	NA	DRD2
C00-D49: Neoplasms	Thyroid cancer diagnosis	C73	TSHR
I00-I99: Diseases of the circulatory system	Angina pectoris	I20	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Anxiety disorder	F32, F40-F42	HTR2A; HTR2C; DRD2
E00-E89: Endocrine, nutritional and metabolic diseases	Obesity	E66	HTR2C; HTR2C
C00-D49: Neoplasms	Thyroid cancer	C73	TSHR
K00-K95: Diseases of the digestive system	Inflammatory bowel disease	K50, K51	DRD2
C00-D49: Neoplasms	Inflammatory disease	C11, C44, K75.9, M00-M25	DRD2
NA: NA	Inflammatory diseases	NA	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Insomnia	F51.0, G47.0	CA2; DRD2
NA: NA	Benign prostatic hypertrophy	NA	DRD2
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Depressive fatigue	R53.82	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Depression	F30-F39	HTR2B; HTR2A; HTR2C
E00-E89: Endocrine, nutritional and metabolic diseases	Diabetes	E23.2, N25.1	HTR2A; HTR2C
C00-D49: Neoplasms	Lymphoma	C81-C86	CA9; HIF1A
I00-I99: Diseases of the circulatory system	Coronary heart disease	I25.1	HTR2B
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Male sexual disorders	F52	DRD3
H00-H59: Diseases of the eye and adnexa	Open-angle glaucoma	H40-H42	CA2
H00-H59: Diseases of the eye and adnexa	Ophthalmic disease	H00-H59	DRD2
J00-J99: Diseases of the respiratory system	Nasal congestion	J34.89	DRD2
NA: NA	Vomiting	NA	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Generalized anxiety disorder	F32, F40-F42, F41.1	HTR2C
K00-K95: Diseases of the digestive system	Gastrointestinal problems	K30-K31, Q40-Q41	DRD2
NA: NA	Malignant essential hypertension	NA	DRD2
NA: NA	Malignant phaeochromocytoma	NA	DRD2
C00-D49: Neoplasms	Clear cell renal cell carcinoma	C64	CA9
H00-H59: Diseases of the eye and adnexa	Glaucoma	H40-H42	CA1; CA1; HTR2A; DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Erectile dysfunction	F52.2, N48.4	DRD4
E00-E89: Endocrine, nutritional and metabolic diseases	Erythropoietic porphyria	E80.0	HTR2A
I00-I99: Diseases of the circulatory system	Maintain blood pressure in hypotensive states	I10	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Major depressive disorder	F32, F33, M32	HTR2C; HTR2C; DRD2
I00-I99: Diseases of the circulatory system	Neurological disease	I21, I22, R52, R52.1-R52.2, R60.9, G89	HTR2C
K00-K95: Diseases of the digestive system	Dermal necrosis	K05	DRD2
I00-I99: Diseases of the circulatory system	Edema associated with congestive heart failure	I50, R60.9	CA2
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Emesis	R11	DRD3; DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychiatric disorder	F01-F99	HTR2A
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychotic disorders	F20-F29	DRD3; HTR2C; DRD2; DRD4
S00-T88: Injury, poisoning and certain other consequences of external causes	Allergy	T78.4	DRD2
G00-G99: Diseases of the nervous system G00-G99	Migraine	G43	HTR2B; HTR2A
G00-G99: Diseases of the nervous system G00-G99	Migraine headaches	G43	HTR2C; DRD2
NA: NA	Edema	NA	CA2
K00-K95: Diseases of the digestive system	Duodenal ulcers	K25-K27	CA2; CA1
I00-I99: Diseases of the circulatory system	Hemorrhoids	I84	HTR2A
I00-I99: Diseases of the circulatory system	Congestive heart failure	I50	HTR2B
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Huntington's disease	F02.2, G10	DRD2
A00-B99: Certain infectious and parasitic diseases	Bacterial infections	A00-B99	DRD2
I00-I99: Diseases of the circulatory system	High blood pressure	I10-I16	CA2
NA: NA	Corneal vascularity	NA	DRD2
J00-J99: Diseases of the respiratory system	Asthma	J45	DRD2
NA: NA	Schizoaffective disorders	NA	DRD2
NA: NA	Hyperaemia	NA	DRD2
K00-K95: Diseases of the digestive system	Gastric motility disorder	K22.4	DRD3
L00-L99: Diseases of the skin and subcutaneous tissue	Fibrosis	L90.5	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Female sexual dysfunction	F52	DRD3
M00-M99: Diseases of the musculoskeletal system and connective tissue	Fibromyalgia	M79.7	HTR2A
C00-D49: Neoplasms	Breast cancer	C50	CA9; DRD2
E00-E89: Endocrine, nutritional and metabolic diseases	Metabolic disorders	E70-E89	HTR2C
E00-E89: Endocrine, nutritional and metabolic diseases	Hyperprolactinemia	E22.1	DRD2
I00-I99: Diseases of the circulatory system	Hypertension	I10-I16	DRD2; DRD2
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	Nausea	R11	DRD2
NA: NA	False perceptions	NA	DRD2
O00-O9A: Pregnancy, childbirth and the puerperium	Postpartum haemorrhage	O72	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Psychosis	F20-F29	DRD2
NA: NA	Primary insomnia	NA	HTR2C
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	Idiopathic thrombocytopenic purpura	D69.3	DRD2
F01-F99: Mental, Behavioral and Neurodevelopmental disorders	Substance dependence	F10-F19	DRD2
C00-D49: Neoplasms	Non-small cell lung cancer	C33-C34	DRD2
C00-D49: Neoplasms	Cancer	C00-C96	CA1; CA9; HIF1A
J00-J99: Diseases of the respiratory system	Bronchitis	J20-J21, J42	DRD2
E00-E89: Endocrine, nutritional and metabolic diseases	Carcinoid syndrome	E34.0	DRD2
C00-D49: Neoplasms	Solid tumours	C00-D48	CA9; HIF1A

Data Section	Select to Download
1. General Info & Plant Usage & Geographical Distribution
2. Human Target Proteins
3. Target Gene Ontology
4. Target KEGG Pathway
5. Related Human Diseases